[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100550699":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":28,"locations":39,"responsibleParty":157,"collaborators":11,"id":159,"slug":160,"hasResults":161,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":11,"eligibilityCriteria":165,"healthyVolunteers":161,"sex":166,"minAge":167,"maxAge":168,"enrollmentInfo":169,"targetDuration":11,"studyType":172,"phases":173,"briefSummary":175,"conditions":176,"keywords":11,"overallStatus":42,"whyStopped":11,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":187},{"fullName":5,"class":6},"TBF Genie Tissulaire","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Therapeutic lens alone","ACTIVE_COMPARATOR",null,[13],"Device: Therapeutic lens alone",{"label":15,"type":16,"description":11,"interventionNames":17},"Therapeutic lens + amniotic membrane (Visio-AMTRIX)","EXPERIMENTAL",[18],"Combination Product: Therapeutic lens + amniotic membrane (Visio-AMTRIX)",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":11},"DEVICE","Therapeutic lens will be apposed on the patient's eye after crosslinking. Therapeutic lens will be maintained without interruption until the first postoperative visit (Day 2) when it will be removed by the investigator.",[9],{"type":25,"name":15,"description":26,"armGroupLabels":27,"otherNames":11},"COMBINATION_PRODUCT","Amniotic membrane (Visio-AMTRIX) will be apposed under therapeutic lens on the patient's eye after crosslinking. Amniotic membrane and therapeutic lens will be maintained without interruption until the first postoperative visit (Day 2) when it will be removed by the investigator.",[15],[29,35],{"name":30,"role":31,"phone":32,"phoneExt":33,"email":34},"Laurence BARNOUIN, MD","CONTACT","0472686909","+33","laurence.barnouin@tbf-lab.com",{"name":36,"role":31,"phone":37,"phoneExt":33,"email":38},"Justine BOSC, MSc","4 72 68 69 11","justine.bosc@tbf-lab.com",[40,57,69,81,93,106,121,133,145],{"facility":41,"status":42,"city":43,"state":11,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"CHU de Brest","RECRUITING","Brest","29609","France","FR",{"type":48,"coordinates":49},"Point",[50,51],-4.48628,48.39029,{"lat":51,"lon":50},[54],{"name":55,"role":56,"phone":11,"phoneExt":11,"email":11},"Béatrice COCHENER-LAMARD, Professor","PRINCIPAL_INVESTIGATOR",{"facility":58,"status":42,"city":59,"state":11,"zip":60,"country":45,"countryCode":46,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Hospices Civils de Lyon","Lyon","69003",{"type":48,"coordinates":62},[63,64],4.84789,45.74906,{"lat":64,"lon":63},[67],{"name":68,"role":56,"phone":11,"phoneExt":11,"email":11},"Carole BURILLON, Professor",{"facility":70,"status":42,"city":71,"state":11,"zip":72,"country":45,"countryCode":46,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Assistance Publique - Hôpitaux de Marseille","Marseille","13005",{"type":48,"coordinates":74},[75,76],5.38107,43.29695,{"lat":76,"lon":75},[79],{"name":80,"role":56,"phone":11,"phoneExt":11,"email":11},"Thierry DAVID, Professor",{"facility":82,"status":42,"city":83,"state":11,"zip":84,"country":45,"countryCode":46,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"CHU de Montpellier","Montpellier","34295",{"type":48,"coordinates":86},[87,88],3.87635,43.61093,{"lat":88,"lon":87},[91],{"name":92,"role":56,"phone":11,"phoneExt":11,"email":11},"Vincent DAIEN, Professor",{"facility":94,"status":95,"city":96,"state":11,"zip":97,"country":45,"countryCode":46,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"CHU de Nantes","NOT_YET_RECRUITING","Nantes","44000",{"type":48,"coordinates":99},[100,101],-1.55336,47.21725,{"lat":101,"lon":100},[104],{"name":105,"role":56,"phone":11,"phoneExt":11,"email":11},"Isabelle ORIGNAC, MD",{"facility":107,"status":42,"city":108,"state":11,"zip":109,"country":45,"countryCode":46,"cosmosGeoPoint":110,"geoPoint":114,"contacts":115},"Hôpital National de la Vision des Quinze-Vingts","Paris","75012",{"type":48,"coordinates":111},[112,113],2.3488,48.85341,{"lat":113,"lon":112},[116,118],{"name":117,"role":56,"phone":11,"phoneExt":11,"email":11},"Juliette KNOERI, MD",{"name":119,"role":120,"phone":11,"phoneExt":11,"email":11},"Vincent BORDERIE, Professor","SUB_INVESTIGATOR",{"facility":122,"status":42,"city":123,"state":11,"zip":124,"country":45,"countryCode":46,"cosmosGeoPoint":125,"geoPoint":129,"contacts":130},"CHU de Saint-Etienne","Saint-Priest-en-Jarez","42270",{"type":48,"coordinates":126},[127,128],4.37678,45.4739,{"lat":128,"lon":127},[131],{"name":132,"role":56,"phone":11,"phoneExt":11,"email":11},"Marie-Caroline TRONE, MD",{"facility":134,"status":42,"city":135,"state":11,"zip":136,"country":45,"countryCode":46,"cosmosGeoPoint":137,"geoPoint":141,"contacts":142},"Hôpitaux Universitaires de Strasbourg","Strasbourg","67000",{"type":48,"coordinates":138},[139,140],7.74553,48.58392,{"lat":140,"lon":139},[143],{"name":144,"role":56,"phone":11,"phoneExt":11,"email":11},"Tristan BOURCIER, Professor",{"facility":146,"status":42,"city":147,"state":11,"zip":148,"country":45,"countryCode":46,"cosmosGeoPoint":149,"geoPoint":153,"contacts":154},"CHU de Toulouse","Toulouse","31300",{"type":48,"coordinates":150},[151,152],1.44367,43.60426,{"lat":152,"lon":151},[155],{"name":156,"role":56,"phone":11,"phoneExt":11,"email":11},"Pierre FOURNIÉ, Professor",{"type":158,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100550699","phase-3-use-of-a-freeze-dried-amniotic-membrane-post-crosslinking-in-subjects-with-progressive-keratoconus-100550699",false,"NCT06450470","Use of a Freeze-dried Amniotic Membrane Post Crosslinking in Subjects With Progressive Keratoconus","Multicenter, Randomized Study Evaluating the Use of a Non-sutured Sterile Freeze-dried Amniotic Membrane Post Crosslinking in Subjects With Progressive Keratoconus","Inclusion Criteria:\n\n* Man or woman between 18 and 65 years old.\n* Indication for accelerated conventional crosslinking.\n* Patient with progressive keratoconus (increase in Kmax of ≥ 0.5 diopters in 3 to 6 months or ≥ 1 diopter in 3 to 12 months with loss of 10 microns on minimum pachymetry in 3 to 12 month).\n* Patient suffering from keratoconus with a compatible topographic form (Kmax ≥ 47.0 diopters (D) and difference inferior-superior of 1.5 D).\n* Patient with a minimum corneal thickness greater than 400 microns.\n* Informed and consenting patient.\n* Patient physically and mentally capable of completing the post-operative pain assessment self-questionnaire.\n* Patient having signed the informed consent of the French Ophthalmology Society for crosslinking.\n* Patient affiliated to a social security system or beneficiary of such a system.\n\nExclusion Criteria:\n\n* Woman without effective means of contraception, pregnant or breastfeeding.\n* Patient who has already benefited from a crosslinking procedure on one of the eyes.\n* Patient with a history of refractive surgery on one of the eyes.\n* Patient with an intracorneal ring segment on one of the eyes.\n* Patient suffering from a serious systemic pathology (autoimmune and\u002For immunodepressive)\n* Patient with a psychiatric pathology.\n* Patient on long-term analgesics and\u002For corticosteroids.\n* Indication of crosslinking outside the classic protocol.\n* Patient with central corneal opacity.\n* Patient suffering from a severe dry eye syndrome or a neurotrophic keratitis.\n* Patient with a history of ocular herpes.\n* Patient with a history of ocular varicella-zoster virus infection.\n* Patient with glaucoma.\n* Patient treated with topical cyclosporine in the last 6 months.\n* Patient deprived of liberty by a judicial or administrative decision.\n* Patient subject to a legal protection measure or unable to express their consent.","ALL","18 Years","65 Years",{"count":170,"type":171},116,"ESTIMATED","INTERVENTIONAL",[174],"PHASE3","Crosslinking is a therapeutic technique used to increase the rigidity of the cornea in order to slow or stop progression of keratoconus. The main complication of the treatment of keratoconus by crosslinking is postoperative pain due to the removal of the corneal epithelium. Currently, the management of pain is done through the administration of artificial tears and paracetamol. The amniotic membrane is a biological tissue used in ophthalmology to treat injuries of the surface of the eye. It has healing and analgesic properties.\n\nThe objective of this multicenter randomized study is to evaluate the benefit of placing an amniotic membrane on the eye post-crosslinking to reduce pain and promote corneal healing.",[177],"Progressive Keratoconus","2025-04-08",{"date":180,"type":181},"2025-04-11","ACTUAL",{"date":183,"type":181},"2024-11-25",{"date":185,"type":171},"2025-11",{"name":5,"class":6},9]